Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,775 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 2,775 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.38, for a total transaction of $123,154.50. Following the sale, the executive vice president now owns 34,888 shares in the company, valued at approximately $1,548,329.44. This represents a 7.37 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Andrew Callos also recently made the following trade(s):

• On Friday, March 14th, Andrew Callos sold 100 shares of Cytokinetics stock. The stock was sold at an average price of $45.00, for a total transaction of $4,500.00.
• On Thursday, March 6th, Andrew Callos sold 3,341 shares of Cytokinetics stock. The shares were sold at an average price of $43.27, for a total value of $144,565.07.

Cytokinetics Trading Up 5.4 %

Shares of Cytokinetics stock traded up $2.33 during mid-day trading on Friday, hitting $45.43. The stock had a trading volume of 3,724,448 shares, compared to its average volume of 1,473,531. The firm has a 50-day moving average of $45.99 and a two-hundred day moving average of $50.04. The firm has a market cap of $5.38 billion, a P/E ratio of -8.44 and a beta of 0.95. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 12-month low of $40.53 and a 12-month high of $75.71.

Remove Ads

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analysts' expectations of $14.26 million. Sell-side analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Institutional Trading of Cytokinetics

A number of hedge funds and other institutional investors have recently modified their holdings of CYTK. Jones Financial Companies Lllp increased its position in shares of Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 374 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in Cytokinetics in the 4th quarter valued at approximately $29,000. AlphaQuest LLC raised its position in Cytokinetics by 113,500.0% in the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 1,135 shares during the period. J.Safra Asset Management Corp lifted its stake in Cytokinetics by 62.1% during the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 671 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in shares of Cytokinetics by 85.8% during the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 842 shares during the period.

Analyst Ratings Changes

Several analysts have commented on the company. JMP Securities reissued a "market outperform" rating and issued a $78.00 price objective on shares of Cytokinetics in a report on Friday, February 7th. HC Wainwright reissued a "buy" rating and issued a $120.00 price target on shares of Cytokinetics in a report on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $72.00 price objective on shares of Cytokinetics in a report on Thursday, February 6th. Stifel Nicolaus assumed coverage on shares of Cytokinetics in a research note on Wednesday, January 22nd. They set a "buy" rating and a $80.00 target price for the company. Finally, Royal Bank of Canada upped their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Cytokinetics presently has an average rating of "Moderate Buy" and a consensus target price of $82.00.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.